1. Academic Validation
  2. Targeting of mTORC1/2 by dihydroevocarpine induces cytotoxicity in acute myeloid leukemia

Targeting of mTORC1/2 by dihydroevocarpine induces cytotoxicity in acute myeloid leukemia

  • J Cell Physiol. 2019 Aug;234(8):13032-13041. doi: 10.1002/jcp.27974.
Silin Zhang 1 Yunhe Xiong 2 Yixian Zhang 3 Hongmei Zhao 4
Affiliations

Affiliations

  • 1 Reproductive Medicine Center, Renmin Hospital of Wuhan University, Wuhan, China.
  • 2 Urology Department, Renmin Hospital of Wuhan University, Wuhan, China.
  • 3 Department of Pediatrics, Huai'an Affiliated Hospital of Xuzhou Medical University, The Second People's Hospital of Huai'an, Huai'an, China.
  • 4 Department of Pathology, Huaiyin Hospital of Huai'an city, Huai'an, China.
Abstract

Interactions between the tumor cells and bone marrow (BM) microenvironment promote survival, growth, and chemoresistance of acute myeloid leukemia (AML). The mTOR pathway plays a key role in mediating the AML-BM microenvironment interactions. Here, we report the anti-AML activity of a natural monomer extracted from the Chinese medicinal herb Evodia rutaecarpa, dihydroevocarpine. Our results showed that dihydroevocarpine-induced cytotoxicity, Apoptosis, and G0/G1 arrest in AML cells, and inhibited the tumor growth in an AML xenograft model. Importantly, our study revealed that the dihydroevocarpine treatment inhibited the mTOR pathway via suppressing the mTORC1/2 activity, and thus overcame the protective effect of the BM microenvironment on AML cells. Taken together, our findings suggest that dihydroevocarpine could be used as a potential anti-AML agent alone or a therapeutic adjunct in AML therapy, particularly in the presence of the BM microenvironment.

Keywords

acute myeloid leukemia (AML); bone marrow (BM) microenvironment; dihydroevocarpine; mTOR complex 1 (mTORC1); mTOR complex 2 (mTORC2).

Figures
Products